De Arcos-Jiménez JC, Sánchez-Reye K, Álvarez-Zavala M, González-Hernández LA, Ramos-Solano M, Andrade-Villanueva JF

Language: Spanish
References: 18
Page: 352-355
PDF size: 573.42 Kb.

ABSTRACT

The natural infection course by the Human Immunodeficiency Virus (HIV) is characterized by the high rates of replication and continuous depletion of CD4+ T lymphocytes, the main target cells, with the Acquired Immunodeficiency Syndrome (AIDS) as a consequence, where opportunistic diseases are present and death is the final outcome. There is a minority group of HIV-infected people who spontaneously control the infection called Elite Controllers (ECs), which has been the subject of intense investigations, with the objective of elucidating the mechanisms by which they naturally control the infection, it is important to mention that the elite controller status is not permanent, some of them can lose virological and immune control and progress to AIDS, so it is important to know the mechanisms associated with the ECs, as well as the factors that lead to the loss of this virological control with the aim of developing strategies that lead to the cure of HIV.

REFERENCES

1. K. R. McCarthy, A. Kirmaier, P. Autissier, and W. E. Johnson, “Evolutionary and Functional Analysis of Old World Primate TRIM5 Reveals the Ancient Emergence of Primate Lentiviruses and Convergent Evolution Targeting a Conserved Capsid Interface,” PLoS Pathog., vol. 11, no. 8, pp. 1–26, 2015.

2. P. M. Sharp and B. H. Hahn, “Origins of HIV and the AIDS pandemic,” Cold Spring Harb. Perspect. Med., vol. 1, no. 1, pp. 1–22, 2011.

3. 3 J. B. Whitney et al., “viraemia in rhesus monkeys,” Nature, vol. 512, no. 7512, pp. 74–77, 2014.

4. F. Edalat, “NIH Public Access,” vol. 40, no. 6, pp. 1301–1315, 2012.

5. P. An and C. A. Winkler, “Host genes associated with HIV / AIDS: advances in gene discovery,” pp. 119–131, 2010.

6. L. Genovese, M. Nebuloni, and M. Alfano, “Cellmediated immunity in elite controllers naturally controlling hiv viral load,” Front. Immunol., vol. 4, no. APR, pp. 1–12, 2013.

7. Y. Madec et al., “Early Control of HIV-1 Infection in Long-Term Nonprogressors Followed Since Diagnosis in the ANRS SEROCO / HEMOCO Cohort,” vol. 50, no. 1, pp. 25–28, 2009.

8. F. Pereyra et al., “relationship to immunologic parameters,” vol. 200, no. February 2008, pp. 984–990, 2013.

9. O. O. Yang, W. G. Cumberland, R. Escobar, D. Liao, and K. W. Chew, “Demographics and natural history of HIV-1-infected spontaneous controllers of viremia,” AIDS, vol. 31, no. 8, pp. 1091–1098, 2017.

10. J. F. Okulicz and O. Lambotte, “Epidemiology and clinical characteristics of elite controllers,” Curr. Opin. HIV AIDS, vol. 6, no. 3, pp. 163–168, 2011.

11. E. Canouï et al., “A subset of extreme human immunodeficiency virus (HIV) controllers is characterized by a small HIV blood reservoir and a weak T-cell activation level,” Open Forum Infect. Dis., vol. 4, no. 2, pp. 1–8, 2017.

12. F. Pereyra et al., “Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy,” J. Infect. Dis., vol. 197, no. 4, pp. 563–571, 2008.

13. E. Gonzalo-gil, U. Ikediobi, and R. E. Sutton, “Mechanisms of Virologic Control and Clinical Characteristics of HIV + Elite / Viremic Controllers,” Yale J. Biol. Med., vol. 90, pp. 245–259, 2017.

14. A. Leon et al., “Rate and predictors of progression in elite and viremic HIV-1 controllers,” AIDS, vol. 30, no. 8, pp. 1209–1220, 2016.

15. M. Pernas et al., “Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection,” J. Virol., vol. 2, no. December, p. JVI.01805-17, 2017.

16. J. M. Benito et al., “Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers,” BMC Med., vol. 16, no. 1, pp. 1–12, 2018.

17. T. A. Crowell et al., “Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection,” J. Infect. Dis., vol. 211, no. 11, pp. 1692–1702, 2015.

18. UNAIDS, “Adults and Adolescents Living with HIV Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults.”